The HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) from the National Institutes of Health (NIH) supports the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications are open to researchers at research institutions in the USA and worldwide. Applicants may apply for up to 1.5 million USD/year for up to 5 years.
Opportunity number: RFA-NS-24-018.
Letters of intent are due on June 10, 2023 and full applications are due on July 10, 2023.
